BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Famous Network programs in Europe and America - 2Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
- 3What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- 4Fascinating Fishing Objections From Around The World
- 55 Language Learning Applications
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- Iran’s Crown Prince Reza Pahlavi backs protests: Join your fellow citizens in the streets
- Chicago reports first rabies-positive dog in 61 years. What we know.
- If someone's always late, is it time blindness, or are they just being rude?
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
- From Dread to Certainty: Individual Accounts of Strengthening
